In a subsequent trial, DCs were engineered with three tumor antigens (tyrosinase, MART-1 and MAGE-A6) to activate multiple CD8 + and CD4+ T cell clones and patients were randomized to receive a one-month course of high-dose systemic IFN-α2b following vaccination or vaccination alone [7]. Here, CD4 is linked to neoplasm.